Table 3.
Univariable and multivariable Cox analysis for mCRPC-free survival and CSS.
| Characteristics | mCRPC-free survival | CSS | ||||||
|---|---|---|---|---|---|---|---|---|
| Univariable analysis | Multivariable analysis | Univariable analysis | Multivariable analysis | |||||
| HR (95% CI) | p value | HR (95% CI) | p value | HR (95% CI) | p value | HR (95% CI) | p value | |
| Age | 1.030 (0.974-1.091) | 0.294 | 1.087 (0.998-1.184) | 0.154a | 0.995 (0.920-1.076) | 0.901 | 0.983 (0.839-1.152) | 0.833c |
| PSA at diagnosis | 0.997 (0.993-1.002) | 0.256 | 0.994 (0.987-1.126) | 0.256a | 0.995 (0.986-1.004) | 0.270 | 0.941 (0.902-1.182) | 0.125c |
| Pathologic Gleason score | ||||||||
| ≤7 | Referent | 0.045 | Referent | 0.198a | Referent | 0.759 | ||
| 8 | 1.257 (0.856-2.175) | 0.077 | 3.911 (0.722-7.176) | 0.114 | 3.582 (0.749-7.936) | 0.942 | ||
| ≥9 | 4.236 (1.445-6.908) | 0.014 | 4.006 (0.858-8.709) | 0.078 | 2.535 (0.815-5.628) | 0.940 | ||
| Pathologic T stage | ||||||||
| T2a-T3a | Referent | 0.233 | Referent | 0.885 | ||||
| T3b | 2.330 (0.819-6.633) | 0.113 | 2.559 (0.856-7.645) | 0.932 | ||||
| T4 | 2.341 (0.795-6.893) | 0.123 | 1.745 (0.762-6.379) | 0.931 | ||||
| Pathologic N stage (N0 vs. N1) | 3.786 (1.87-10.858) | 0.010 | 0.370 (0.020-6.720) | 0.502a | 0.363 (0.170-0.774) | 0.009 | 3.245 (0.611-17.231) | 0.167c |
| Number of metastases (1-3 vs. 4-5) | 2.552 (1.164-5.598) | 0.019 | 1.285 (0.482-3.425) | 0.617a | 5.551 (1.705-8.069) | 0.004 | 2.174 (0.548-8.632) | 0.270c |
| Positive surgical margin (No vs. Yes) | 1.358 (0.586-3.146) | 0.475 | 3.383( 0.741-15.451) | 0.116 | ||||
| Postoperative adjuvant RT (No vs. Yes) | 0.390 (0.147-0.835) | 0.039 | 0.113 (0.130-0.422) | 0.013a | 0.950 (0.286-3.156) | 0.933 | ||
| T-CTC (continuous) | 1.123 (1.063-1.187) | <0.001 | 1.182 (1.052-1.329) | 0.035a | 1.179 (1.082-1.286) | <0.001 | 1.311 (1.110-1.549) | 0.001c |
| E-CTC (continuous) | 1.234 (0.931-1.636) | 0.144 | 1.341 (0.906-1.985) | 0.143 | ||||
| M-CTC (continuous) | 1.303 (1.152-1.473) | <0.001 | 1.259 (1.081-1.466) | 0.038a | 1.455 (1.215-1.743) | <0.001 | 1.386 (1.135-1.693) | 0.001c |
| Bi-CTC (continuous) | 1.128 (1.036-1.228) | 0.005 | 0.873 (0.730-1.044) | 0.137a | 1.145 (1.026-1.278) | 0.015 | 1.050 (0.913-1.208) | 0.491c |
| T-CTC (<5 vs. ≥5) | 4.404 (1.946-9.969) | <0.001 | 4.150 (1.453-7.852) | 0.020b | 5.005 (1.374-8.232) | 0.015 | 3.362 (1.684-8.159) | 0.024d |
| M-CTC (<2 vs. ≥2) | 3.277 (1.495-7.182) | 0.003 | 3.341 (1.334-8.363) | 0.011b | 3.911 (1.198-6.769) | 0.024 | 3.912 (1.160-7.194) | 0.028d |
mCRPC, metastatic castration-resistant prostate cancer; CSS, cancer specific survival; HR, hazard ratio; CI, confidence interval; CTC, circulating tumor cell; T-CTC, total circulating tumor cell; M-CTC, mesenchymal circulating tumor cell; E-CTC, epithelial circulating tumor cell; Bi-CTC, biphenotypic circulating tumor cell; RT, radiotherapy.
aAdjusted for: T-CTC (continuous), M-CTC (continuous), Bi-CTC (continuous), age, PSA at diagnosis, pathologic Gleason score, pathologic N stage, number of metastases and postoperative adjuvant RT.
bAdjusted for: T-CTC (<5 vs. ≥5), M-CTC (<2 vs. ≥2), Bi-CTC (continuous), age, PSA at diagnosis, pathologic Gleason score, pathologic N stage, number of metastases and postoperative adjuvant RT.
cAdjusted for: T-CTC (continuous), M-CTC (continuous), Bi-CTC (continuous), age, PSA at diagnosis, pathologic N stage and number of metastases.
dAdjusted for: T-CTC (<5 vs. ≥5), M-CTC (<2 vs. ≥2), Bi-CTC (continuous), age, PSA at diagnosis, pathologic N stage and number of metastases.